title: [Triple-gene therapy in Parkinson disease (ProSavin): toward a putaminal dopamine factory?].
authors.affiliation: Service de neurologie, unité des mouvements anormaux, Centre expert inter-régional de la maladie de Parkinson, hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, 67000 Strasbourg, France. Electronic address: mathieu.anheim@chru-strasbourg.fr.
authors.forename: M
authors.initials: M
authors.lastname: Anheim
mesh_terms: D017321:Clinical Trials, Phase I as Topic / Q000639:trends; D017322:Clinical Trials, Phase II as Topic / Q000639:trends; D004298:Dopamine / Q000378:metabolism*; D005602:France; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage; D005968:Glutamate Decarboxylase / Q000008:administration & dosage / Q000235:genetics; D006801:Humans; D057967:Infusions, Intraventricular; D010300:Parkinson Disease / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D010865:Pilot Projects; D011699:Putamen / Q000378:metabolism* / Q000473:pathology; D006113:United Kingdom
chemical_list: D005968:Glutamate Decarboxylase; D004298:Dopamine